Publikation: Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease
Dateien
Datum
Autor:innen
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
DOI (zitierfähiger Link)
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Publikationsstatus
Erschienen in
Zusammenfassung
The most common reason behind dementia is Alzheimer's disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
Schlagwörter
Konferenz
Rezension
Zitieren
ISO 690
DALVI, Tanay, Bhaskar DEWANGAN, Rudradip DAS, Jyoti RANI, Suchita D. SHINDE, Nazmina VHORA, Alok JAIN, Bichismita SAHU, 2020. Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease. In: Central Nervous System Agents in Medicinal Chemistry. Bentham Science Publishers. 2020, 20(3), pp. 157-176. ISSN 1871-5249. eISSN 1875-6166. Available under: doi: 10.2174/1871524920666201021164805BibTex
@article{Dalvi2020-10-21Drugs-52874, year={2020}, doi={10.2174/1871524920666201021164805}, title={Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease}, number={3}, volume={20}, issn={1871-5249}, journal={Central Nervous System Agents in Medicinal Chemistry}, pages={157--176}, author={Dalvi, Tanay and Dewangan, Bhaskar and Das, Rudradip and Rani, Jyoti and Shinde, Suchita D. and Vhora, Nazmina and Jain, Alok and Sahu, Bichismita} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52874"> <dc:contributor>Rani, Jyoti</dc:contributor> <dc:creator>Shinde, Suchita D.</dc:creator> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52874"/> <dc:contributor>Dewangan, Bhaskar</dc:contributor> <dcterms:title>Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease</dcterms:title> <dc:creator>Rani, Jyoti</dc:creator> <dc:creator>Das, Rudradip</dc:creator> <dc:contributor>Shinde, Suchita D.</dc:contributor> <dc:contributor>Das, Rudradip</dc:contributor> <dc:creator>Jain, Alok</dc:creator> <dcterms:issued>2020-10-21</dcterms:issued> <dc:language>eng</dc:language> <dc:creator>Sahu, Bichismita</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>Dalvi, Tanay</dc:contributor> <dc:contributor>Sahu, Bichismita</dc:contributor> <dc:rights>terms-of-use</dc:rights> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dc:creator>Dewangan, Bhaskar</dc:creator> <dc:creator>Dalvi, Tanay</dc:creator> <dc:contributor>Vhora, Nazmina</dc:contributor> <dc:creator>Vhora, Nazmina</dc:creator> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/> <dcterms:abstract xml:lang="eng">The most common reason behind dementia is Alzheimer's disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.</dcterms:abstract> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-17T10:51:46Z</dcterms:available> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-17T10:51:46Z</dc:date> <dc:contributor>Jain, Alok</dc:contributor> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> </rdf:Description> </rdf:RDF>